Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria E Suarez-Almazor

Showing results (191-200 of 243) with videos related to

Pageof 25
Sort By:
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic CholangiocarcinomaTimothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Journal for Immunotherapy of Cancer|April 18, 2019
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literatureNoha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, et al.
JCO Clinical Cancer Informatics|March 21, 2019
Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer TherapyJessica P Hwang, Danmeng Huang, John M Vierling, et al.
Seminars in Arthritis and Rheumatism|October 23, 2016
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSimon Tarp, Daniel E Furst, Anna Dossing, et al.
JMIR Cancer|October 25, 2024
Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability StudyMaria A Lopez-Olivo, Maria E Suarez-Almazor, Gabrielle F Duhon, et al.
Seminars in Arthritis and Rheumatism|June 2, 2022
Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working groupJosé B Negrón, Maria A Lopez-Olivo, Loreto Carmona, et al.
Arthritis and Rheumatism|June 2, 2006
Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosusJavier P Berrios-Rivera, Richard L Street, Maria G Garcia Popa-Lisseanu, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literatureHoussein Safa, Daniel H Johnson, Van Anh Trinh, et al.
Cancers|August 12, 2023
Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint InhibitorsMaria A Lopez-Olivo, Johncy J Kachira, Maryam Buni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 29, 2020
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitorsMaria E Suarez-Almazor, Xerxes Pundole, Noha Abdel-Wahab, et al.
Pageof 25

Showing results (191-200 of 243) with videos related to

Sort By:
Pageof 25
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic CholangiocarcinomaTimothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Journal for Immunotherapy of Cancer|April 18, 2019
Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literatureNoha Abdel-Wahab, Houssein Safa, Ala Abudayyeh, et al.
JCO Clinical Cancer Informatics|March 21, 2019
Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer TherapyJessica P Hwang, Danmeng Huang, John M Vierling, et al.
Seminars in Arthritis and Rheumatism|October 23, 2016
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSimon Tarp, Daniel E Furst, Anna Dossing, et al.
JMIR Cancer|October 25, 2024
Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability StudyMaria A Lopez-Olivo, Maria E Suarez-Almazor, Gabrielle F Duhon, et al.
Seminars in Arthritis and Rheumatism|June 2, 2022
Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working groupJosé B Negrón, Maria A Lopez-Olivo, Loreto Carmona, et al.
Arthritis and Rheumatism|June 2, 2006
Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosusJavier P Berrios-Rivera, Richard L Street, Maria G Garcia Popa-Lisseanu, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literatureHoussein Safa, Daniel H Johnson, Van Anh Trinh, et al.
Cancers|August 12, 2023
Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint InhibitorsMaria A Lopez-Olivo, Johncy J Kachira, Maryam Buni, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 29, 2020
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitorsMaria E Suarez-Almazor, Xerxes Pundole, Noha Abdel-Wahab, et al.
Pageof 25